Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Value of monitoring negative emotional bias in primary care in England for personalised antidepressant treatment: a modelling study.

Simon J, Harmer CJ, Kingslake J, Dawson GR, Dourish CT, Goodwin GM.

Evid Based Ment Health. 2019 Nov;22(4):145-152. doi: 10.1136/ebmental-2019-300109. Epub 2019 Sep 27.

PMID:
31562131
2.

Predicting treatment response to antidepressant medication using early changes in emotional processing.

Browning M, Kingslake J, Dourish CT, Goodwin GM, Harmer CJ, Dawson GR.

Eur Neuropsychopharmacol. 2019 Jan;29(1):66-75. doi: 10.1016/j.euroneuro.2018.11.1102. Epub 2018 Nov 22.

3.

Overview of the clinical implementation of a study exploring social withdrawal in patients with schizophrenia and Alzheimer's disease.

Bilderbeck AC, Penninx BWJH, Arango C, van der Wee N, Kahn R, Winter-van Rossum I, Hayen A, Kas MJ, Post A, Dawson GR.

Neurosci Biobehav Rev. 2019 Feb;97:87-93. doi: 10.1016/j.neubiorev.2018.06.019. Epub 2018 Jun 22.

4.

Evidence That Sedative Effects of Benzodiazepines Involve Unexpected GABAA Receptor Subtypes: Quantitative Observation Studies in Rhesus Monkeys.

Duke AN, Meng Z, Platt DM, Atack JR, Dawson GR, Reynolds DS, Tiruveedhula VVNPB, Li G, Stephen MR, Sieghart W, Cook JM, Rowlett JK.

J Pharmacol Exp Ther. 2018 Jul;366(1):145-157. doi: 10.1124/jpet.118.249250. Epub 2018 May 2.

5.

The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial.

Kingslake J, Dias R, Dawson GR, Simon J, Goodwin GM, Harmer CJ, Morriss R, Brown S, Guo B, Dourish CT, Ruhé HG, Lever AG, Veltman DJ, van Schaik A, Deckert J, Reif A, Stäblein M, Menke A, Gorwood P, Voegeli G, Pérez V, Browning M.

Trials. 2017 Nov 23;18(1):558. doi: 10.1186/s13063-017-2247-2.

6.

Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls.

Smith J, Browning M, Conen S, Smallman R, Buchbjerg J, Larsen KG, Olsen CK, Christensen SR, Dawson GR, Deakin JF, Hawkins P, Morris R, Goodwin G, Harmer CJ.

Mol Psychiatry. 2018 May;23(5):1127-1133. doi: 10.1038/mp.2017.104. Epub 2017 May 23.

7.

Erratum: A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.

Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M, Wafford K, McCarthy A, Barth V, Witkin JM.

Neuropsychopharmacology. 2016 Sep;41(10):2624. doi: 10.1038/npp.2016.78. Epub 2016 Aug 11.

8.

Experimental Medicine in Psychiatry New Approaches in Schizophrenia, Depression and Cognition.

Dawson GR.

Curr Top Behav Neurosci. 2016;28:475-97. doi: 10.1007/7854_2015_5016. Review.

PMID:
27418068
9.

Cognitive and oculomotor performance in subjects with low and high schizotypy: implications for translational drug development studies.

Koychev I, Joyce D, Barkus E, Ettinger U, Schmechtig A, Dourish CT, Dawson GR, Craig KJ, Deakin JF.

Transl Psychiatry. 2016 May 17;6:C. doi: 10.1038/tp.2016.64.

10.

Comparing the actions of lanicemine and ketamine in depression: key role of the anterior cingulate.

Downey D, Dutta A, McKie S, Dawson GR, Dourish CT, Craig K, Smith MA, McCarthy DJ, Harmer CJ, Goodwin GM, Williams S, Deakin JF.

Eur Neuropsychopharmacol. 2016 Jun;26(6):994-1003. doi: 10.1016/j.euroneuro.2016.03.006. Epub 2016 Apr 28.

PMID:
27133029
11.

A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.

Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M, Wafford K, McCarthy A, Barth V, Witkin JM.

Neuropsychopharmacology. 2016 Jun;41(7):1803-12. doi: 10.1038/npp.2015.348. Epub 2015 Nov 20. Erratum in: Neuropsychopharmacology. 2016 Sep;41(10):2624.

12.

Investigating virtual reality navigation in amnestic mild cognitive impairment using fMRI.

Migo EM, O'Daly O, Mitterschiffthaler M, Antonova E, Dawson GR, Dourish CT, Craig KJ, Simmons A, Wilcock GK, McCulloch E, Jackson SH, Kopelman MD, Williams SC, Morris RG.

Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2016;23(2):196-217. doi: 10.1080/13825585.2015.1073218. Epub 2015 Aug 3.

PMID:
26234803
13.

Alterations in working memory networks in amnestic mild cognitive impairment.

Migo EM, Mitterschiffthaler M, O'Daly O, Dawson GR, Dourish CT, Craig KJ, Simmons A, Wilcock GK, McCulloch E, Jackson SH, Kopelman MD, Williams SC, Morris RG.

Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2015;22(1):106-27. doi: 10.1080/13825585.2014.894958. Epub 2014 Mar 12.

PMID:
24617815
14.

The effects of ketamine and risperidone on eye movement control in healthy volunteers.

Schmechtig A, Lees J, Perkins A, Altavilla A, Craig KJ, Dawson GR, William Deakin JF, Dourish CT, Evans LH, Koychev I, Weaver K, Smallman R, Walters J, Wilkinson LS, Morris R, Williams SC, Ettinger U.

Transl Psychiatry. 2013 Dec 10;3:e334. doi: 10.1038/tp.2013.109.

15.

Precompetitive consortium approach to validation of the next generation of biomarkers in schizophrenia.

Dourish CT, Dawson GR.

Biomark Med. 2014;8(1):5-8. doi: 10.2217/bmm.13.89. No abstract available.

16.

Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate.

Diaper A, Rich AS, Wilson SJ, Craig K, Dourish CT, Dawson GR, Nutt DJ, Bailey JE.

Hum Psychopharmacol. 2013 Nov;28(6):562-75.

PMID:
23955418
17.

Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy.

Schmechtig A, Lees J, Grayson L, Craig KJ, Dadhiwala R, Dawson GR, Deakin JF, Dourish CT, Koychev I, McMullen K, Migo EM, Perry C, Wilkinson L, Morris R, Williams SC, Ettinger U.

Psychopharmacology (Berl). 2013 May;227(2):331-45. doi: 10.1007/s00213-013-2973-4. Epub 2013 Feb 22.

PMID:
23430159
18.

Combined NK₁ antagonism and serotonin reuptake inhibition: effects on emotional processing in humans.

Harmer CJ, Dawson GR, Dourish CT, Favaron E, Parsons E, Fiore M, Zucchetto M, Bifone A, Poggesi I, Fernandes S, Alexander RC, Goodwin GM.

J Psychopharmacol. 2013 May;27(5):435-43. doi: 10.1177/0269881112472558. Epub 2013 Feb 12.

PMID:
23407644
19.

Reinforcing effects of compounds lacking intrinsic efficacy at α1 subunit-containing GABAA receptor subtypes in midazolam- but not cocaine-experienced rhesus monkeys.

Shinday NM, Sawyer EK, Fischer BD, Platt DM, Licata SC, Atack JR, Dawson GR, Reynolds DS, Rowlett JK.

Neuropsychopharmacology. 2013 May;38(6):1006-14. doi: 10.1038/npp.2012.265. Epub 2012 Dec 27.

20.

The effect of a clinically effective and non-effective dose of lorazepam on 7.5% CO₂-induced anxiety.

Diaper A, Papadopoulos A, Rich AS, Dawson GR, Dourish CT, Nutt DJ, Bailey JE.

Hum Psychopharmacol. 2012 Nov;27(6):540-8. doi: 10.1002/hup.2261. Epub 2012 Oct 2.

PMID:
23027657
21.

Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic.

Diaper A, Osman-Hicks V, Rich AS, Craig K, Dourish CT, Dawson GR, Nutt DJ, Bailey JE.

J Psychopharmacol. 2013 Feb;27(2):135-45. doi: 10.1177/0269881112443742. Epub 2012 Apr 19.

PMID:
22516666
22.

A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-center double-blind placebo-controlled study.

Koychev I, McMullen K, Lees J, Dadhiwala R, Grayson L, Perry C, Schmechtig A, Walters J, Craig KJ, Dawson GR, Dourish CT, Ettinger U, Wilkinson L, Williams S, Deakin JF, Barkus E.

Eur Neuropsychopharmacol. 2012 Jul;22(7):469-81. doi: 10.1016/j.euroneuro.2011.10.005. Epub 2011 Dec 3.

PMID:
22137565
23.

Validating the inhalation of 7.5% CO(2) in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD).

Bailey JE, Dawson GR, Dourish CT, Nutt DJ.

J Psychopharmacol. 2011 Sep;25(9):1192-8. doi: 10.1177/0269881111408455. Review.

PMID:
21994314
24.

Special issue on CNS experimental medicine.

Dawson GR, Dourish CT, Goodwin GM.

J Psychopharmacol. 2011 Sep;25(9):1145-7. doi: 10.1177/0269881111415342. No abstract available.

PMID:
21994313
25.

Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety.

Bailey JE, Papadopoulos A, Diaper A, Phillips S, Schmidt M, van der Ark P, Dourish CT, Dawson GR, Nutt DJ.

J Psychopharmacol. 2011 Sep;25(9):1199-206. doi: 10.1177/0269881111400650. Epub 2011 May 9.

PMID:
21555331
26.

Validation of experimental medicine methods in psychiatry: the P1vital approach and experience.

Dawson GR, Craig KJ, Dourish CT.

Biochem Pharmacol. 2011 Jun 15;81(12):1435-41. doi: 10.1016/j.bcp.2011.03.013. Epub 2011 Apr 1. Review.

PMID:
21440531
27.

Contribution of GABA(A) receptors containing α3 subunits to the therapeutic-related and side effects of benzodiazepine-type drugs in monkeys.

Fischer BD, Atack JR, Platt DM, Reynolds DS, Dawson GR, Rowlett JK.

Psychopharmacology (Berl). 2011 May;215(2):311-9. doi: 10.1007/s00213-010-2142-y. Epub 2010 Dec 30.

28.

Scopolamine disrupts hippocampal activity during allocentric spatial memory in humans: an fMRI study using a virtual reality analogue of the Morris Water Maze.

Antonova E, Parslow D, Brammer M, Simmons A, Williams S, Dawson GR, Morris R.

J Psychopharmacol. 2011 Sep;25(9):1256-65. doi: 10.1177/0269881110379285. Epub 2010 Sep 7.

PMID:
20823079
29.

Occupancy of human brain GABA(A) receptors by the novel α5 subtype-selective benzodiazepine site inverse agonist α5IA as measured using [¹¹C]flumazenil PET imaging.

Eng W, Atack JR, Bergstrom M, Sanabria S, Appel L, Dawson GR, Sciberras D, Hargreaves RJ, Langstrom B, Burns HD.

Neuropharmacology. 2010 Dec;59(7-8):635-9. doi: 10.1016/j.neuropharm.2010.07.024. Epub 2010 Aug 7.

PMID:
20696179
30.

Agomelatine facilitates positive versus negative affective processing in healthy volunteer models.

Harmer CJ, de Bodinat C, Dawson GR, Dourish CT, Waldenmaier L, Adams S, Cowen PJ, Goodwin GM.

J Psychopharmacol. 2011 Sep;25(9):1159-67. doi: 10.1177/0269881110376689. Epub 2010 Jul 21.

PMID:
20660010
31.

Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist.

Atack JR, Hallett DJ, Tye S, Wafford KA, Ryan C, Sanabria-Bohórquez SM, Eng WS, Gibson RE, Burns HD, Dawson GR, Carling RW, Street LJ, Pike A, De Lepeleire I, Van Laere K, Bormans G, de Hoon JN, Van Hecken A, McKernan RM, Murphy MG, Hargreaves RJ.

J Psychopharmacol. 2011 Mar;25(3):329-44. doi: 10.1177/0269881109354928. Epub 2010 Feb 15.

PMID:
20156926
32.

MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans.

Atack JR, Wafford KA, Street LJ, Dawson GR, Tye S, Van Laere K, Bormans G, Sanabria-Bohórquez SM, De Lepeleire I, de Hoon JN, Van Hecken A, Burns HD, McKernan RM, Murphy MG, Hargreaves RJ.

J Psychopharmacol. 2011 Mar;25(3):314-28. doi: 10.1177/0269881109354927. Epub 2010 Feb 10.

PMID:
20147571
33.

Discriminative stimulus effects of L-838,417 (7-tert-butyl-3-(2,5-difluoro-phenyl)-6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine): role of GABA(A) receptor subtypes.

Licata SC, Platt DM, Rüedi-Bettschen D, Atack JR, Dawson GR, Van Linn ML, Cook JM, Rowlett JK.

Neuropharmacology. 2010 Feb;58(2):357-64. doi: 10.1016/j.neuropharm.2009.10.004. Epub 2009 Oct 22.

34.

Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes.

Ator NA, Atack JR, Hargreaves RJ, Burns HD, Dawson GR.

J Pharmacol Exp Ther. 2010 Jan;332(1):4-16. doi: 10.1124/jpet.109.158303. Epub 2009 Sep 29.

35.

In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist.

Atack JR, Maubach KA, Wafford KA, O'Connor D, Rodrigues AD, Evans DC, Tattersall FD, Chambers MS, MacLeod AM, Eng WS, Ryan C, Hostetler E, Sanabria SM, Gibson RE, Krause S, Burns HD, Hargreaves RJ, Agrawal NG, McKernan RM, Murphy MG, Gingrich K, Dawson GR, Musson DG, Petty KJ.

J Pharmacol Exp Ther. 2009 Nov;331(2):470-84. doi: 10.1124/jpet.109.157636. Epub 2009 Aug 24.

PMID:
19704033
36.

The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates.

Atack JR, Eng WS, Gibson RE, Ryan C, Francis B, Sohal B, Dawson GR, Hargreaves RJ, Burns HD.

Br J Pharmacol. 2009 Jul;157(5):796-803. doi: 10.1111/j.1476-5381.2009.00216.x. Epub 2009 Apr 30.

37.

The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women.

Halford JC, Boyland EJ, Cooper SJ, Dovey TM, Huda MS, Dourish CT, Dawson GR, Wilding JP.

J Psychopharmacol. 2010 Jan;24(1):99-109. doi: 10.1177/0269881108095195. Epub 2008 Aug 28.

PMID:
18755818
38.

Guest editor's note.

Reynolds DS, Dawson GR.

Pharmacol Biochem Behav. 2008 Jul;90(1):v. No abstract available.

PMID:
18668705
39.

Age-related neural activity during allocentric spatial memory.

Antonova E, Parslow D, Brammer M, Dawson GR, Jackson SH, Morris RG.

Memory. 2009 Feb;17(2):125-43. doi: 10.1080/09658210802077348.

PMID:
18608980
40.

Alpha2-containing GABA(A) receptors are involved in mediating stimulant effects of cocaine.

Morris HV, Dawson GR, Reynolds DS, Atack JR, Rosahl TW, Stephens DN.

Pharmacol Biochem Behav. 2008 Jul;90(1):9-18. doi: 10.1016/j.pbb.2008.02.010. Epub 2008 Feb 12.

PMID:
18358520
41.

Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist.

Nutt DJ, Besson M, Wilson SJ, Dawson GR, Lingford-Hughes AR.

Neuropharmacology. 2007 Dec;53(7):810-20. Epub 2007 Aug 16.

PMID:
17888460
42.

Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands.

Fradley RL, Guscott MR, Bull S, Hallett DJ, Goodacre SC, Wafford KA, Garrett EM, Newman RJ, O'Meara GF, Whiting PJ, Rosahl TW, Dawson GR, Reynolds DS, Atack JR.

J Psychopharmacol. 2007 Jun;21(4):384-91. Epub 2006 Nov 8.

PMID:
17092983
43.

L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors.

Atack JR, Bayley PJ, Seabrook GR, Wafford KA, McKernan RM, Dawson GR.

Neuropharmacology. 2006 Nov;51(6):1023-9. Epub 2006 Oct 12.

PMID:
17046030
44.

The proconvulsant effects of the GABAA alpha5 subtype-selective compound RY-080 may not be alpha5-mediated.

Atack JR, Bayley PJ, Fletcher SR, McKernan RM, Wafford KA, Dawson GR.

Eur J Pharmacol. 2006 Oct 24;548(1-3):77-82. Epub 2006 May 19.

PMID:
16962577
45.
46.

An inverse agonist selective for alpha5 subunit-containing GABAA receptors improves encoding and recall but not consolidation in the Morris water maze.

Collinson N, Atack JR, Laughton P, Dawson GR, Stephens DN.

Psychopharmacology (Berl). 2006 Nov;188(4):619-28. Epub 2006 Apr 22.

PMID:
16633803
47.

Effects of reinforcement schedule on facilitation of operant extinction by chlordiazepoxide.

Leslie JC, Shaw D, Gregg G, McCormick N, Reynolds DS, Dawson GR.

J Exp Anal Behav. 2005 Nov;84(3):327-38.

48.

Rat pharmacokinetics and pharmacodynamics of a sustained release formulation of the GABAA alpha5-selective compound L-655,708.

Atack JR, Pike A, Clarke A, Cook SM, Sohal B, McKernan RM, Dawson GR.

Drug Metab Dispos. 2006 May;34(5):887-93. Epub 2006 Feb 2.

PMID:
16455808
49.

The in vivo properties of pagoclone in rat are most likely mediated by 5'-hydroxy pagoclone.

Atack JR, Pike A, Marshall G, Stanley J, Lincoln R, Cook SM, Lewis RT, Blackaby WP, Goodacre SC, McKernan RM, Dawson GR, Wafford KA, Reynolds DS.

Neuropharmacology. 2006 May;50(6):677-89. Epub 2006 Jan 20.

PMID:
16430927
50.

An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition.

Dawson GR, Maubach KA, Collinson N, Cobain M, Everitt BJ, MacLeod AM, Choudhury HI, McDonald LM, Pillai G, Rycroft W, Smith AJ, Sternfeld F, Tattersall FD, Wafford KA, Reynolds DS, Seabrook GR, Atack JR.

J Pharmacol Exp Ther. 2006 Mar;316(3):1335-45. Epub 2005 Dec 2.

PMID:
16326923

Supplemental Content

Loading ...
Support Center